On-Campus Solar PV Lab: Component Selection is Only the Beginning

The work of the Solar PV Team is to design and install Solar PV systems which enable our clients to fulfill their mission in the presence of unreliable or non-existent electrical power. In order to experiment with different Solar PV configurations and train new members, the Solar PV team last year designed a Solar Lab to be installed in and next to Frey 70. This work paralleled the design/component selection typically performed prior to an installation site trip. This year, the team modeled the efforts typically done at the installation site by building and configuring the Solar Lab design. This poster will focus on the lessons learned about decisions that need to be made in the field to convert a Component Selection level design into a Functioning PV System.https://mosaic.messiah.edu/engr2021/1015/thumbnail.jp

On-Campus Solar PV Lab: Component Selection is Only the Beginning

The work of the Solar PV Team is to design and install Solar PV systems which enable our clients to fulfill their mission in the presence of unreliable or non-existent electrical power. In order to experiment with different Solar PV configurations and train new members, the Solar PV team last year designed a Solar Lab to be installed in and next to Frey 70. This work paralleled the design/component selection typically performed prior to an installation site trip. This year, the team modeled the efforts typically done at the installation site by building and configuring the Solar Lab design. This poster will focus on the lessons learned about decisions that need to be made in the field to convert a Component Selection level design into a Functioning PV System.https://mosaic.messiah.edu/engr2021/1003/thumbnail.jp

Solar PV - Equipping the Future

The Solar PV team has installed several solar power systems for various partners in the developing world. Most recently, the team installed a solar-powered well pump at the Living Love Ministries Children’s Home in Ol Kalou, Kenya. As is true for all the previous installations, the team gained a wealth of valuable knowledge and experience on the trip to Kenya. A problem the team faces is that a lot of that experience gained leaves when seniors graduate. With the goal of passing on our knowledge and experience to future generations of the Solar PV team, we have been constructing a solar lab at Messiah for experimentation and training. We also are developing a curriculum to teach new team members about solar power and provide a framework for preserving new knowledge the team obtains in the future. Throughout the 2019-2020 year, the solar team has made significant progress towards the completion of these projects.https://mosaic.messiah.edu/engr2020/1011/thumbnail.jp

Designing a Solar PV System for Tree 4 Hope

The Solar Photovoltaics (PV) team designs and installs solar electricity systems in developing countries where power is less reliable or non-existent. Starting in 2020, the Solar PV team began collaborating with Tree 4 Hope—a nonprofit organization that partners with an orphanage near Guatemala City, Guatemala. Over the past year, the team has designed a solar system to be installed at the orphanage which will provide them with a cleaner and cheaper source of electricity. Thus far, the overall 5 kW solar panel system design including lead-acid batteries has been completed. Key components of the system consisting of the system controller, two charge controllers and the inverter have been programmed and tested, by plugging them into existing elements of the solar lab system, in preparation for installation in Guatemala. This poster details the progress accomplished this year in the design, testing, and programming of the Solar PV system including wiring considerations and communication with in-country suppliers for installation at the orphanage during May of this year. Funding for this work provided by The Collaboratory for Strategic Partnerships and Applied Research.https://mosaic.messiah.edu/engr2022/1016/thumbnail.jp

Considerations for establishing and maintaining international research collaboration: the example of chemotherapy-induced peripheral neurotoxicity (CIPN)—a white paper

PurposeThis white paper provides guidance regarding the process for establishing and maintaining international collaborations to conduct oncology/neurology-focused chemotherapy-induced peripheral neurotoxicity (CIPN) research.MethodsAn international multidisciplinary group of CIPN scientists, clinicians, research administrators, and legal experts have pooled their collective knowledge regarding recommendations for establishing and maintaining international collaboration to foster advancement of CIPN science.ResultsExperts provide recommendations in 10 categories: (1) preclinical and (2) clinical research collaboration; (3) collaborators and consortiums; (4) communication; (5) funding; (6) international regulatory standards; (7) staff training; (8) data management, quality control, and data sharing; (9) dissemination across disciplines and countries; and (10) additional recommendations about feasibility, policy, and mentorship.ConclusionRecommendations to establish and maintain international CIPN research collaboration will promote the inclusion of more diverse research participants, increasing consideration of cultural and genetic factors that are essential to inform innovative precision medicine interventions and propel scientific discovery to benefit cancer survivors worldwide.Relevance to inform research policyOur suggested guidelines for establishing and maintaining international collaborations to conduct oncology/neurology-focused chemotherapy-induced peripheral neurotoxicity (CIPN) research set forth a challenge to multinational science, clinical, and policy leaders to (1) develop simple, streamlined research designs; (2) address logistical barriers; (3) simplify and standardize regulatory requirements across countries; (4) increase funding to support international collaboration; and (5) foster faculty mentorship

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

To identify novel genes associated with ALS, we undertook two lines of investigation. We carried out a genome-wide association study comparing 20,806 ALS cases and 59,804 controls. Independently, we performed a rare variant burden analysis comparing 1,138 index familial ALS cases and 19,494 controls. Through both approaches, we identified kinesin family member 5A (KIF5A) as a novel gene associated with ALS. Interestingly, mutations predominantly in the N-terminal motor domain of KIF5A are causative for two neurodegenerative diseases: hereditary spastic paraplegia (SPG10) and Charcot-Marie-Tooth type 2 (CMT2). In contrast, ALS-associated mutations are primarily located at the C-terminal cargo-binding tail domain and patients harboring loss-of-function mutations displayed an extended survival relative to typical ALS cases. Taken together, these results broaden the phenotype spectrum resulting from mutations in KIF5A and strengthen the role of cytoskeletal defects in the pathogenesis of ALS.Peer reviewe

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) with slow upright vital capacity (SVC) of ≥60% were randomized 1:1:1:1 to reldesemtiv 150, 300, or 450 mg twice daily (bid) or placebo; active treatment was 12 weeks with 4-week follow-up. Primary endpoint was change in percent predicted SVC at 12 weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) and muscle strength mega-score. Results: Patients (N = 458) were enrolled; 85% completed 12-week treatment. The primary analysis failed to reach statistical significance (p = 0.11); secondary endpoints showed no statistically significant effects (ALSFRS-R, p = 0.09; muscle strength mega-score, p = 0.31). Post hoc analyses pooling all active reldesemtiv-treated patients compared against placebo showed trends toward benefit in all endpoints (progression rate for SVC, ALSFRS-R, and muscle strength mega-score (nominal p values of 0.10, 0.01 and 0.20 respectively)). Reldesemtiv was well tolerated, with nausea and fatigue being the most common side effects. A dose-dependent decrease in estimated glomerular filtration rate was noted, and transaminase elevations were seen in approximately 5% of patients. Both hepatic and renal abnormalities trended toward resolution after study drug discontinuation. Conclusions: Although the primary efficacy analysis did not demonstrate statistical significance, there were trends favoring reldesemtiv for all three endpoints, with effect sizes generally regarded as clinically important. Tolerability was good; modest hepatic and renal abnormalities were reversible. The impact of reldesemtiv on patients with ALS should be assessed in a pivotal Phase 3 trial. (ClinicalTrials.gov Identifier: NCT03160898)

International validation of the Erasmus GBS Respiratory Insufficiency Score

none13Objective: This study aimed to validate the Erasmus Guillain-Barré syndrome Respiratory Insufficiency Score in the International Guillain-Barré Syndrome Outcome Study cohort, and to improve its performance and region-specificity. Methods: We examined data from the first 1,500 included patients, aged ≥6 years and not ventilated prior to study entry. Patients with a clinical variant or mild symptoms were also included. Outcome was mechanical ventilation within the first week from study entry. Model performance was assessed regarding the discriminative ability (area under the receiver operating characteristic curve) and the calibration (observed versus predicted probability of mechanical ventilation), in the full cohort and in Europe/North America and Asia separately. We recalibrated the model to improve its performance and region-specificity. Results: In the group of 1,023 eligible patients (Europe/North America n = 842, Asia n = 104, other n = 77), 104 (10%) required mechanical ventilation within the first week from study entry. Area under the curve values were ≥ 0.80 for all validation subgroups. Mean observed proportions of mechanical ventilation were lower than predicted risks: full cohort 10% vs. 21%, Europe/North America 9% vs. 21% and Asia 17% vs. 23%. After recalibration, predicted risks for the full cohort and Europe/North America corresponded to observed proportions. Interpretation: This prospective, international, cohort study validated the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score, and showed that the model can be used in the full spectrum of Guillain-Barré syndrome patients. In addition, a more accurate, region-specific version of the model was developed for patients from Europe/North America. This article is protected by copyright. All rights reserved.noneDoets, Alex Y; Walgaard, Christa; Lingsma, Hester F; Islam, Badrul; Papri, Nowshin; Yamagishi, Yuko; Kusunoki, Susumu; Briani C; Dimachkie, Mazen M; Waheed, Waqar; Kolb, Noah; Gorson, Kenneth C; Jacobs, Bart CDoets, Alex Y; Walgaard, Christa; Lingsma, Hester F; Islam, Badrul; Papri, Nowshin; Yamagishi, Yuko; Kusunoki, Susumu; Briani, C; Dimachkie, Mazen M; Waheed, Waqar; Kolb, Noah; Gorson, Kenneth C; Jacobs, Bart